Update your tester profile Login
  • Studies for Particpants Diagnosed with Type 2 Diabetes

    Throughout 2015, Prism will be conducting several studies for participants diagnosed with type 2 diabetes.  These studies will be posted on our website once recuritment is officially underway.  

    Don't see a study listed?  Maybe a study is posted but it's not a match for you?  That's ok, we still want to hear from you!  Each study will have an unique set of qualifications.  Register with our database now so we can identify the right study for you as soon as it becomes availble.

    The information you provide is only used to help us determine your eligibility for current and future studies. We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies. We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

  • Study 1419: Participants with Type 1 or Type 2 Diabetes

    Research Purpose: Study 1419 is designed to evaluate an investigational injected medication being developed for the treatment of diabetic kidney disease in participants with either type 1 or type 2 diabetes and various degrees of kidney damage. 

    Minimum Screening Qualifications:


    Males are allowed to participate


    Females are allowed to participate.


    • Type 1 Diabetes: Ages 21-80
    • Type 2 Diabetes: Ages 30-80

    Body Mass Index (BMI)

    Less than or equal to 45 kg/m²


    No weight requirements

    Tobacco/Nicotine Use

    Tobacco use is prohibited while at clinic.  Use of tobacco at other times is allowed

    Alcohol/Drug Abuse History

    History of drug/alcohol abuse will be considered on a case by case basis.

    Health History


    • History of or currently requiring dialysis
    • History of kidney or other organ transplantation

    Other exclusions related to health history may apply. Prism staff will review participants’ health history to determine eligibility.



    • Ongoing treatment of systemic immunosuppression therapy

    Other medications exclusions may apply, however; stable use of many medications is allowed.  Prism staff will review participants’ medication lists to determine eligibility.


    Study Time Commitment: For participants who qualify based on screening evaluations, study participation will last for approximately 1 year.

    Inpatient Stays

    • There are no overnight stays during this study

    Outpatient Visits

    • Following the two part screen, there are 16 outpatient visits over the course of approximately 54 weeks.
    • Three outpatient visits will last between 3-4 hours.  The remaining 13 outpatient visits will last approximately 45 minutes


    Compensation for study participation time: Up to $1,450.00.




    V1 09FEB2015  1419VPI


Recruitment and Volunteer Demographics

Prism Clinical Research recognizes the need to continually grow our diverse volunteer database populations. Through a multi-faceted enrollment process that includes a dedicated recruitment department, collaborative physician partnerships, advertising and subject referral programs, Prism Clinical Research can deliver Phase I-II results in the following populations:

  • HIV

  • Hepatic

  • Renal (Pre-ESRD, ESRD)

  • Type 2 Diabetes

  • Obesity

  • Healthy Male/Female/Elderly

  • Gilbert’s subset

  • Rheumatoid Arthritis

  • Epilepsy

  • Multiple Sclerosis
  • GI (IBS & Crohn’s)

  • Celiac
  • COPD, Allergy and Asthma

  • High Cholesterol

  • Hypertensive

  • Alzheimer's Disease
  • Ophthalmology

  • Slow Metabolizers

  • Osteoporosis
  • Osteoarthritis
  • Lupus

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.